15 active not recruiting. 15 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Active not recruiting 15 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment BI 765423, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | Boehringer Ingelheim | 81 | 2025-11-13 | 2026-10-27 |
| A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis CAL101, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | Calluna Pharma AS | 150 | 2025-06-20 | 2026-04-27 |
| WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) MTX-463, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | Mediar Therapeutics | 168 | 2025-05-05 | 2026-10-15 |
| A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. Buloxibutid, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Active not recruiting | Vicore Pharma AB | 378 | 2024-12-09 | 2026-11-02 |
| A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) ENV-101, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease | Phase 2 | Active not recruiting | Endeavor Biomedicines, Inc. | 213 | 2024-11-15 | 2026-02-24 |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis AP01, Placebo - Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Active not recruiting | Avalyn Pharma Inc. | 398 | 2024-04-03 | 2026-11-05 |
| Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF) ME-015 (Suplatast Tosilate), Identical placebo - Idiopathic Pulmonary Fibrosis, Cough | Phase 2 | Active not recruiting | Melius Pharma AB | 40 | 2024-04-01 | 2025-04-09 |
| MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Axatilimab, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | Syndax Pharmaceuticals | 145 | 2023-12-11 | 2026-03-27 |
| Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF DWN12088, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | Daewoong Pharmaceutical Co. LTD. | 102 | 2022-07-29 | 2026-07-16 |
| LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Placebo, Pirfenidone, Deupirfenidone - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | PureTech | 240 | 2022-07-22 | 2025-10-16 |
| Xenon MRI and Progressive ILD Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment - Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Active not recruiting | Duke University | 60 | 2022-07-19 | 2026-06-11 |
| Anlotinib Capsules in the Treatment for IPF/PF-ILDs Anlotinib, Placebo - Interstitial Lung Diseases | Phase 2 | Active not recruiting | First Affiliated Hospital of Wenzhou Medical University | 30 | 2021-09-28 | 2026-06-05 |
| Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis Sirolimus - Pulmonary Fibrosis, COVID-19 Pneumonia | Phase 2 / Phase 3 | Active not recruiting | University of Chicago | 60 | 2021-07-09 | 2025-12-15 |
| Phase ll Study of HEC585 in Patients With IPF HEC585, Pirfenidone, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | Sunshine Lake Pharma Co., Ltd. | 270 | 2021-06-30 | 2026-04-21 |
| Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis Saracatinab, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 / Phase 2 | Active not recruiting | National Jewish Health | 49 | 2020-11-12 | 2024-11-14 |
Idiopathic Pulmonary Fibrosis (13) · Fibrosis (2) · Lung Diseases, Interstitial (2) · Alveolitis, Extrinsic Allergic (1) · Chronic Cough (1) · Cough (1) · Post-Acute COVID-19 Syndrome (1) · Respiration Disorders (1)
Lung Diseases (15) · Respiratory Tract Diseases (15) · Lung Diseases, Interstitial (13) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Fibrosis (4) · COVID-19 (1) · Chronic Disease (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Disease Attributes (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1)
pirfenidone (2) · BID protein, human (1) · LY2940680 (1) · MO 113 (1) · Sirolimus (1) · Tablets (1) · anlotinib (1) · axatilimab (1) · compound 21 (1) · idelalisib (1) · suplatast tosilate (1)
Avalyn Pharma Inc. (1) · Boehringer Ingelheim (1) · Calluna Pharma AS (1) · Daewoong Pharmaceutical Co. LTD. (1) · Duke University (1) · Endeavor Biomedicines, Inc. (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Mediar Therapeutics (1) · Melius Pharma AB (1) · National Jewish Health (1) · PureTech (1) · Sunshine Lake Pharma Co., Ltd. (1) · Syndax Pharmaceuticals (1) · University of Chicago (1) · Vicore Pharma AB (1)
United States (10) · South Korea (7) · Australia (6) · Belgium (6) · Canada (6) · Italy (6) · United Kingdom (6) · Argentina (5) · France (5) · Germany (5) · Spain (5) · Mexico (3) · Netherlands (3) · Poland (3) · Romania (3)
Annetine Gelijns, PhD (1) · Ayodeji Adegunsoye, MD, MS (1) · Camilla Graham, MD (1) · Danielle Antin-Ozerkis, MD (1) · Gregory Downey, MD (1) · Lisa Lancaster, M.D. (1) · Maria Padilla, MD (1) · Robert M Tighe, MD (1) · Susan Mathai, MD (1) · Todd Astor, MD (1) · Xiaoying Huang, Docter (1)
PMID 36948586, PMID 41124966, PMID 41448793, PMID 42085224
2025 (2), UG3TR002445 (1)